AXT Exercises Over-Allotment, Raising $82.5M Additional Equity Amid Permit-Gated InP Narrative

What happened

AXT announced that underwriters exercised their over-allotment option, purchasing an additional 1.28M shares at $64.25/share, generating approximately $82.5M in gross proceeds. This follows the recent public offering of 8.56M shares, bringing total equity raised to over $550M in the past six months. The company is using the capital to fund InP capacity expansion, but our master report highlights that AXT remains a permit-gated exporter with no visibility on U.S. InP permits. FY2025 revenue fell to $88.3M and GAAP gross margin compressed to 12.7%, reflecting the structural challenges of manufacturing in China under export controls. At $54.2, the stock prices aggressive InP growth that depends on two binary variables: repeatable export approvals and measurable capacity execution, both unproven.

Implication

The additional equity raise provides liquidity but does not address the core thesis breaker: the inability to resume routine U.S. InP shipments. Without clear evidence of sustained InP revenue growth above Q3'25 levels and GAAP gross margin exceeding 20%, the stock remains a speculative bet on permit and execution outcomes. Current valuation already prices in the bull case, leaving little room for error. Investors should await two consecutive quarters of demonstrable progress in both permit flow and capacity utilization before considering entry.

Thesis delta

No material shift; the over-allotment exercise confirms the company's aggressive equity financing strategy but does not alter the fundamental risk of permit dependency. The investment thesis still hinges on observable proof points around export cadence and operational execution, which remain absent.